For those who do not take the WSJ an interesting quote - 

"With a data picture this cloudy, it isn’t hard to imagine the FDA asking for another late-stage efficacy study before any approval. That would likely push any possible approval back by years, quelling today’s optimism. What’s more, even if regulators sign off, insurance companies will likely need to be persuaded that the drug can slow disease progression before they pay for it."